Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting

Tenofovir disoproxil fumarate (TDF) has increasingly been replaced by tenofovir alafenamide (TAF) because of reduced kidney and bone toxicity with TAF. This switch has, however, caused worsening of lipid concentrations in clinical trials, but data from any real-world setting are scarce. The objectiv...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	AIDS patient care and STDs 2019-12, Vol.33 (12), p.500-506
Hauptverfasser:	Kauppinen, Kai Juhani, Kivelä, Pia, Sutinen, Jussi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - adverse effects Adenine - analogs & derivatives Adenine - therapeutic use Adult Anti-HIV Agents - adverse effects Anti-HIV Agents - therapeutic use Anti-Retroviral Agents - therapeutic use Antiretroviral agents Antiretroviral drugs Cholesterol Cholesterol - blood Cholesterol, LDL - blood Cholesterol, LDL - drug effects Clinical trials Creatinine Demographics Density Dyslipidemia Dyslipidemias - blood Dyslipidemias - drug therapy Dyslipidemias - virology Female Glomerular Filtration Rate High density lipoprotein HIV HIV Infections - drug therapy HIV Seropositivity - drug therapy Human immunodeficiency virus Humans Hypolipidemic Agents - administration & dosage Kidneys Lipid Metabolism - drug effects Lipids Lipids - blood Low density lipoprotein Male Metabolic disorders Middle Aged Patients Retrospective Studies Risk Factors Statistical analysis Switching Tenofovir Tenofovir - adverse effects Tenofovir - therapeutic use Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!